Ellenhorn JD - Search Results

1

T lymphocyte activation following OKT3 treatment.

Ellenhorn JD, Woodle ES, Thistlethwaite JR, Bluestone JA. Ellenhorn JD, et al. Curr Surg. 1990 Nov-Dec;47(6):458-9. Curr Surg. 1990. PMID: 2279409 No abstract available.

2

Activation of human T cells in vivo following treatment of transplant recipients with OKT3.

Ellenhorn JD, Woodle ES, Ghobreal I, Thistlethwaite JR, Bluestone JA. Ellenhorn JD, et al. Transplantation. 1990 Oct;50(4):608-12. doi: 10.1097/00007890-199010000-00016. Transplantation. 1990. PMID: 2145669

3

Dose-dependent activation of murine T cells following in vivo administration of anti-murine CD3.

Ellenhorn JD, Hirsch R, Hartley JP, Bluestone JA. Ellenhorn JD, et al. Transplant Proc. 1989 Feb;21(1 Pt 1):1013-4. Transplant Proc. 1989. PMID: 2523110 No abstract available.

4

Immunopotentiation of anti-viral and anti-tumor immune responses using anti-T cell receptor antibodies and mitogens.

Newell KA, Ellenhorn JD, Hirsch R, Bluestone JA. Newell KA, et al. Among authors: ellenhorn jd. Ann N Y Acad Sci. 1991 Dec 30;636:279-87. doi: 10.1111/j.1749-6632.1991.tb33458.x. Ann N Y Acad Sci. 1991. PMID: 1793214 Review.

5

In vivo T-cell activation by staphylococcal enterotoxin B prevents outgrowth of a malignant tumor.

Newell KA, Ellenhorn JD, Bruce DS, Bluestone JA. Newell KA, et al. Among authors: ellenhorn jd. Proc Natl Acad Sci U S A. 1991 Feb 1;88(3):1074-8. doi: 10.1073/pnas.88.3.1074. Proc Natl Acad Sci U S A. 1991. PMID: 1899481 Free PMC article.

6

Mechanism of tumor rejection in anti-CD3 monoclonal antibody-treated mice.

Ellenhorn JD, Schreiber H, Bluestone JA. Ellenhorn JD, et al. J Immunol. 1990 Apr 1;144(7):2840-6. J Immunol. 1990. PMID: 1969454

7

In vivo administration of anti-CD3 prevents malignant progressor tumor growth.

Ellenhorn JD, Hirsch R, Schreiber H, Bluestone JA. Ellenhorn JD, et al. Science. 1988 Oct 28;242(4878):569-71. doi: 10.1126/science.2902689. Science. 1988. PMID: 2902689

8

In vivo administration of anti-CD3 monoclonal antibody can activate immune responses thus preventing malignant tumor growth.

Hirsch R, Ellenhorn JD, Bluestone JA. Hirsch R, et al. Among authors: ellenhorn jd. Princess Takamatsu Symp. 1988;19:237-43. Princess Takamatsu Symp. 1988. PMID: 2978618

9

Treatment with monoclonal anti-CD3 antibody protects against lethal Sendai virus infection by induction of natural killer cells.

Kast WM, Bluestone JA, Heemskerk MH, Spaargaren J, Voordouw AC, Ellenhorn JD, Melief CJ. Kast WM, et al. Among authors: ellenhorn jd. J Immunol. 1990 Oct 1;145(7):2254-9. J Immunol. 1990. PMID: 2168920

10

CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model.

Espenschied J, Lamont J, Longmate J, Pendas S, Wang Z, Diamond DJ, Ellenhorn JD. Espenschied J, et al. Among authors: ellenhorn jd. J Immunol. 2003 Mar 15;170(6):3401-7. doi: 10.4049/jimmunol.170.6.3401. J Immunol. 2003. PMID: 12626601

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

92 results

Search Page

Filters